Literature DB >> 24636587

Aggressive antiplatelet treatment for acute branch atheromatous disease type infarcts: a 12-year prospective study.

Yasumasa Yamamoto1, Yoshinari Nagakane, Masahiro Makino, Tomoyuki Ohara, Takashi Koizumi, Naoki Makita, Ichiro Akiguchi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24636587      PMCID: PMC4235423          DOI: 10.1111/ijs.12200

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


× No keyword cloud information.
Penetrating artery infarcts that are predominantly caused by occlusion at the vessel orifices of larger caliber penetrating arteries by atheromatous plaque can represent a distinctive stroke entity as intracranial branch atheromatous disease (BAD) 1. BAD often shows progressive motor deficits leading to severe disability 2. Thrombolytic therapy by tissue plasminogen activator has not been demonstrated to be effective for BAD 3. We designed a combined use of antiplatelet agents for BAD. During 12 years, 313 consecutive patients with BAD located within the territories of lenticulostriate arteries (LSAs) and anterior pontine arteries (APAs) were prospectively collected. Treatment protocols are as follows: phase 1 (2001–2005, n = 105), the medical treatment that was considered best; phase 2 (2005–2009, n = 104), a combined treatment of argatroban, cilostazol, and edaravone; and phase 3 (2009–20012, n = 104), additional clopidogrel on top of the phase 2 protocol. Functional outcome was assessed by the modified Rankin scale (mRS) at one-month after stroke onset. As a result, in the total population, the phase 2 and the phase 3 showed better outcome than the phase 1 (P = 0·0004 and P < 0·0001). In the LSA infarct group, the phase 2 and the phase 3 showed better outcome than the phase 1 (P = 0·046 and P = 0·0001). The phase 3 showed better outcome than the phase 2 (P = 0·018). In the APA infarct group, the phase 2 and the phase 3 showed better outcome than the phase 1 (P = 0·0004 and P = 0·0006) (see Fig. 1). Cilostazol appeared to be more effective for the infarcts of the APA that branch off from the basilar artery with a diameter of 200–300 micrometers, whereas clopidogrel is more effective for the infarcts of the LSA of 700–800 micrometers that turns sharply and forms a curve or a real loop. The actions of vasodilatation and endothelial protection in cilostazol and inhibition of shear-induced platelet activation in clopidogrel might work effectively 4,5.
Figure 1

Upper LSA group, lower APA group.

Upper LSA group, lower APA group.
  5 in total

Review 1.  Intracranial branch atheromatous disease: a neglected, understudied, and underused concept.

Authors:  L R Caplan
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

2.  Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits.

Authors:  Yasumasa Yamamoto; Tomoyuki Ohara; Masashi Hamanaka; Akiko Hosomi; Aiko Tamura; Ichiro Akiguchi
Journal:  J Neurol Sci       Date:  2011-03-13       Impact factor: 3.181

3.  Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease.

Authors:  Ichiro Deguchi; Takeshi Hayashi; Yuji Kato; Harumitsu Nagoya; Yasuko Ohe; Takuya Fukuoka; Hajime Maruyama; Yohsuke Horiuchi; Norio Tanahashi
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-12-14       Impact factor: 2.136

4.  Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.

Authors:  Ayako Hashimoto; Goro Miyakoda; Yoshimi Hirose; Toyoki Mori
Journal:  Atherosclerosis       Date:  2006-03-20       Impact factor: 5.162

5.  Clopidogrel inhibits shear-induced platelet function.

Authors:  James L Orford; Scott Kinlay; Mark R Adams; Daniel I Simon; Andrew P Selwyn
Journal:  Platelets       Date:  2002-05       Impact factor: 3.862

  5 in total
  4 in total

1.  A retrospective study of branch atheromatous disease: Analyses of risk factors and prognosis.

Authors:  Yang Liu; Yuan-Teng Fan; Yu-Min Liu; Tao Wang; Hong-Liang Feng; Guang-Zhi Liu; Bin Mei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-02-22

2.  Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease.

Authors:  Bin Liu; Hong Zhang; Rong Wang; Hongdang Qu; Yifei Sun; Wanlong Zhang; Shuye Zhang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

3.  Elevated Release of Beta-thromboglobulin and Platelet Factor 4 in Cerebral Infarction Patients with Branch Atheromatous Disease: A Preliminary Report.

Authors:  Akiyoshi Yokote; Kazutoshi Hashimoto; Ryu Bikei; Hidetoshi Nakamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-09-15       Impact factor: 1.742

4.  Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study.

Authors:  Xiangbo Wu; Yang Liu; Chuang Nie; Zhiming Kang; Qunfeng Wang; Dong Sun; Huagang Li; Yumin Liu; Bin Mei
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.